Literature DB >> 9767110

Expression and characterization of human group V phospholipase A2.

Y Chen1, E A Dennis.   

Abstract

Group V phospholipase A2 (GV-PLA2) has been shown to be involved in signal transduction and inflammatory processes in cellular studies, but the physical and biochemical properties of this important enzyme have been unclear. We report the over-expression and characterization of GV-PLA2. The GV-PLA2 cDNA was synthesized from human heart polyA+ mRNA by RT-PCR, and an expression construct containing the GV-PLA2 was established. After expression in Escherichia coli cells, the protein was solubilized and purified to homogeneity in a single step using nickel affinity chromatography. The purified GV-PLA2 protein was folded to form active enzyme. The recombinant GV-PLA2 has an absolute requirement for Ca2+ for enzymatic activity. The optimum pH for this enzyme is pH 8.5 in Tris-HCl buffer with sonicated vesicles as substrate. GV-PLA2 preferentially hydrolyzes phosphatidylethanolamine (PE) vesicles compared to phosphatidylcholine (PC) vesicles. However, hydrolysis of PC and PE is equivalent in mixed vesicles of the phospholipids. The fatty acid preference of GV-PLA2 is linoleoyl>palmitoyl>arachidonyl with a PC head group and sonicated vesicles. 3-(3-Actamide-1-benzyl-2-ethylindolyl-5-oxy)propane phosphonic acid (LY311727), a potent inhibitor of human group IIA PLA2, strongly inhibits GV-PLA2 with an IC50 value of about 36 nM which is comparable to its inhibition of group IIA PLA2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767110     DOI: 10.1016/s0005-2760(98)00098-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Cloning and expression of group IB phospholipase A2 isoforms in the red sea bream, Pagrus major.

Authors:  N Iijima; Y Fujikawa; Y Tateishi; Y Takashima; S Uchiyama; M Esaka
Journal:  Lipids       Date:  2001-05       Impact factor: 1.880

2.  In vivo validation of signaling pathways regulating human monocyte chemotaxis.

Authors:  Ashish Bhattacharjee; Ravi S Mishra; Gerald M Feldman; Martha K Cathcart
Journal:  J Immunol Methods       Date:  2007-12-18       Impact factor: 2.303

3.  Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

Authors:  Hiroyasu Sato; Rina Kato; Yuki Isogai; Go-ichi Saka; Mitsuhiro Ohtsuki; Yoshitaka Taketomi; Kei Yamamoto; Kae Tsutsumi; Joe Yamada; Seiko Masuda; Yukio Ishikawa; Toshiharu Ishii; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shinji Hatakeyama; Shuntaro Hara; Ichiro Kudo; Hiroyuki Itabe; Makoto Murakami
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

4.  Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.

Authors:  Varnavas D Mouchlis; Dimitris Limnios; Maroula G Kokotou; Efrosini Barbayianni; George Kokotos; J Andrew McCammon; Edward A Dennis
Journal:  J Med Chem       Date:  2016-04-28       Impact factor: 7.446

5.  Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2.

Authors:  Varnavas D Mouchlis; Christophe Morisseau; Bruce D Hammock; Sheng Li; J Andrew McCammon; Edward A Dennis
Journal:  Bioorg Med Chem       Date:  2016-05-10       Impact factor: 3.641

6.  VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A2.

Authors:  P N Bernatchez; M V Winstead; E A Dennis; M G Sirois
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

7.  Role of cytosolic phospholipase A2 in cytokine-stimulated prostaglandin release by human gallbladder cells.

Authors:  E M Grossmann; W E Longo; J E Mazuski; N Panesar; D L Kaminski
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

8.  Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes.

Authors:  Georgia Antonopoulou; Efrosini Barbayianni; Victoria Magrioti; Naomi Cotton; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  Bioorg Med Chem       Date:  2008-11-01       Impact factor: 3.641

9.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

10.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.